Oricell advanced its GPC3-targeted autologous CAR T therapy, Ori-C101, into a confirmatory registration phase II trial for GPC3-positive advanced hepatocellular carcinoma, according to the provided content. The program is positioned as the first GPC3-directed immune cell therapy and the first CAR T therapy for liver cancer to reach that stage of development. The move indicates Oricell is converting earlier clinical signals into a late-stage pathway designed to support labeling decisions. The liver cancer population may also benefit from CAR T differentiation tied to GPC3 antigen targeting. For competitors and partners, it raises the bar for upcoming CAR T programs in solid tumors by setting a near-term benchmark for confirmatory trial expectations in hepatocellular carcinoma.